Share on Facebook
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Acorda Therapeutics Inc.
Type Public
Traded as NASDAQACOR FWBCDG
Industry Health care
Biotechnology
Founded 1995 (1995)[1]
Founder(s) Ron Cohen
Headquarters Ardsley, New York, United States
Key people Ron Cohen
Andrew R. Blight
Products Zanaflex
Ampyra
Revenue Increase US$292.2 Million (FY 2011)[2]
Operating income Increase US$35.1 Million (FY 2011)[2]
Net income Increase US$30.6 Million (FY 2011)[2]
Total assets Increase US$379.5 Million (FY 2011)[2]
Total equity Increase US$205.2 Million (FY 2011)[2]
Employees 328 (February, 2012) [2]
Website Acorda.com

Acorda Therapeutics is a biotechnology company based in Ardsley, New York. Acorda Therapeutics develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex and Ampyra in the United States.

Contents

History [edit]

Corporate governance [edit]

As of December 31, 2008 (2008-12-31) the members of the board of directors of Acorda Therapeutics are:[4] Ron Cohen, Barry Greene, John Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, Ian F. Smith, and Wise Young.

Products [edit]

Products on the market [edit]

Products under development [edit]

References [edit]

External links [edit]

Hoover's


Wikipedia content is licensed under the GNU Free Document License or Creative Commons CC-BY-SA
Loading...
Loading...
Top Videos
Latest Videos

Here you can share your comments or contribute with more information, content, resources or links about this topic.